Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis

Kim, Song Yee; Kim, Jungho; Kim, Deok Ryun; Kang, Young Ae; Bong, Sungyoung; Lee, Jonghee; Kim, Su Yeon; Lee, Nam Suk; Sim, Bora; Cho, Sang Nae; Kim, Young Sam; Lee, Hyejon

doi:10.1186/s12879-018-3144-3

Cited by 22 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRP and IP-10 have been mostly evaluated in combination to determine if they can be used to increase the performance of differential diagnosis in TB [ 71 ]. Similar to other findings, that identified elevated concentrations of soluble IP-10 in plasma, serum or urine from PTB patients [ 72 , 73 , 74 ], this study found a declining tendency of IP-10 levels in patients that turned culture negative after anti-TB drug therapy compared to the levels at the time of initiation of treatment. Thus, the lack of treatment response could be associated with persistent high IP-10 levels.…”

Section: Discussionsupporting

confidence: 90%

Prediction of Treatment Outcome with Inflammatory Biomarkers after 2 Months of Therapy in Pulmonary Tuberculosis Patients: Preliminary Results

et al. 2021

View full text Add to dashboard Cite

Pro-inflammatory mediators play an important role in the pathogenesis of pulmonary tuberculosis. Consecutively, 26 pulmonary tuberculosis patients were enrolled in our study based on the exclusion criteria. We have used Spearman’s correlation analysis, hierarchical clustering and regression modelling to evaluate the association of 11 biomarkers with culture status after antituberculosis treatment. The results of our study demonstrated that six inflammatory biomarkers of 11, C-reactive protein (CRP), white blood cells (WBC), neutrophils, interferon gamma inducible protein 10, C-reactive protein (CRP) to albumin ratio (CAR) and neutrophil to albumin ratio (NAR), were significantly associated with culture negativity. The predictive ability of a composite model of seven biomarkers was superior to that of any single biomarker based on area under the receiver operating characteristic curve (AUC) analysis, indicating an excellent prediction efficacy (AUC:0.892; 95% CI:0.732-1.0). We also found that the highest significant trends and lower levels of CRP and IP-10 were observed in the two-month treated tuberculosis (TB) patients. We believe that our study may be valuable in providing preliminary results for an additional strategy in monitoring and management of the clinical outcome of pulmonary tuberculosis. Using a panel of predictors added a superior value in predicting culture status after anti-TB therapy.

show abstract

Section: Discussionsupporting

confidence: 90%

Prediction of Treatment Outcome with Inflammatory Biomarkers after 2 Months of Therapy in Pulmonary Tuberculosis Patients: Preliminary Results

et al. 2021

View full text Add to dashboard Cite

show abstract

“…These results support the research done by other groups [26][27][28][29][30], confirming the suitability of this marker for TB diagnosis. As opposed to TB diagnostic tests based on the IFNγ concentrations (IGRA), which require an incubation period with Mtb antigens, IP-10 has been shown in ours and other studies [26,[31][32][33] to be increased in serum, plasma and urine of TB patients without requiring further stimulation. Of note, in our work IFNγ was rejected for further analysis in the preliminary screening, as it did not show significant differences between groups.…”

Section: Discussionmentioning

confidence: 52%

Identification of candidate host serum and saliva biomarkers for a better diagnosis of active and latent tuberculosis infection

et al. 2020

View full text Add to dashboard Cite

In our work, we aim to identify new candidate host biomarkers to discriminate between active TB patients (n = 28), latent infection (LTBI; n = 27) and uninfected (NoTBI; n = 42) individuals. For that, active TB patients and their contacts were recruited that donated serum and saliva samples. A multiplex assay was performed to study the concentration of different cytokines, chemokines and growth factors. Proteins with significant differences between groups were selected and logistic regression and the area under the ROC curve (AUC) was used to assess the diagnostic accuracy. The best marker combinations that discriminate active TB from NoTBI contacts were [IP-10 + IL-7] in serum and [Fractalkine + IP-10 + IL-1α + VEGF] in saliva. Best discrimination between active TB and LTBI was achieved using [IP-10 + BCA-1] in serum (AUC = 0.83) and IP-10 in saliva (p = 0.0007; AUC = 0.78). The levels of TNFα (p = 0.003; AUC = 0.73) in serum and the combination of [Fractalkine +IL-12p40] (AUC = 0.83) in saliva, were able to differentiate between NoTBI and LTBI contacts. In conclusion, different individual and combined protein markers could help to discriminate between active TB and both uninfected and latently-infected contacts. The most promising ones include [IP-10 + IL-7], [IP-10 + BCA-1] and TNFα in serum and [Fractalkine + IP-10 + IL-1α + VEGF], IP-10 and [Fractalkine+IL-12p40] in saliva.

show abstract

“…IP-10 levels increase in patients with active pulmonary TB and decrease when TB treatment is complete. 19 This study aims to analyze the accuracy of the diagnosis based on the detection of the CXCL10 gene in the urine of patients with suspected pulmonary TB. The results of this study are expected to determine the accuracy of the CXCL10 gene detection method in urine as a laboratory tool for diagnosis of pulmonary TB.…”

Section: Resultsmentioning

confidence: 99%

Diagnosis Based on Detection of CXCL10 in Urine as Biomarker for The Determining Diagnosis of Active Lung Tuberculosis

Mertaniasih

Ananda

Soedarsono

et al. 2021

IJTID

View full text Add to dashboard Cite

Tuberculosis diagnosis is an important component in decreasing TB incidence and prevalence. Because of the difficulty to collect sputum in some cases, urine specimens are used as it is easier to garner. One of the biomarkers in urine that can be used to diagnose pulmonary TB is IP-10, which can be represented by the CXCL10 gene. The study aims to determine the accuracy of diagnosis based on detection of the CXCL10 gene in urine as a biomarker for the patients with suspected pulmonary TB in Dr. Soetomo Hospital in Surabaya from November 2019 until March 2020. Thus, this is an observative laboratory research with a cross-sectional study. CXCL10 gene was examined using PCR for 36 urine samples, and then, the data, together with the medical records of clinical manifestations of pulmonary TB, GeneXpert MTB /RIF, blood count, and thorax radiograph, were processed using IBM SPSS Statistics 26. The results of the GeneXpert MTB/RIF and thorax radiograph criteria show positive results of pulmonary TB, which were 44.4% and 69.4% respectively. CXCL10 gene was not found in all urine of healthy people (negative), while 2.8% (1/36 samples) positive CXCL10 gene was found in a patient with positive GeneXpert, also with negative clinical manifestations and urine culture. In this study, the accuracy of diagnosis based on detection of the CXCL10 gene in urine for diagnosis of active pulmonary TB was 2.8%. Future research is needed to improve the methods, among them are bigger size of urine samples and clearer medical history of patients.

show abstract

Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis

Cited by 22 publications

References 22 publications

Prediction of Treatment Outcome with Inflammatory Biomarkers after 2 Months of Therapy in Pulmonary Tuberculosis Patients: Preliminary Results

Prediction of Treatment Outcome with Inflammatory Biomarkers after 2 Months of Therapy in Pulmonary Tuberculosis Patients: Preliminary Results

Identification of candidate host serum and saliva biomarkers for a better diagnosis of active and latent tuberculosis infection

Diagnosis Based on Detection of CXCL10 in Urine as Biomarker for The Determining Diagnosis of Active Lung Tuberculosis

Contact Info

Product

Resources

About